The results from the CiPA Phase II multi-site, blinded validation study are now in. The CiPA team conclusively demonstrated the utility of human stem cell-derived cardiomyocytes to detect drug-induced arrhythmia effects. We are proud that the Maestro MEA system played a pivotal role in the study. We would also like to thank all the Maestro MEA users at big pharma for making us look great.
Congratulations Dr Daniel Millard and the CiPA Myocyte team on the publication of the CiPA Myocyte Pilot Study. A first of its kind, the CiPA Myocyte assay, proposes using beating human stem cell-derived heart cells, known as cardiomyocytes, to identify drugs that promote the irregular beating of the heart.
We are proud that the Maestro MEA system played a pivotal role in the study. Click here to learn more about the CiPA Myocyte Study and the Maestro MEA platform.
Neurological research has changed profoundly since the discovery of human induced pluripotent stem cells (iPSC), ten years ago. New methods to efficiently generate patient-derived neuronal culture provide unprecedented opportunities to gain new insights into a range of neurological and psychiatric disorders. In addition, breakthroughs in genetics and omics analysis are making molecular profiling of neurons much more accessible and thorough.
At Axion BioSystems we understand the need to explore life’s circuitry.
Many neurological disorders are highly debilitating, and the current treatment options are limited to symptom reduction rather than providing a cure. Advances in differentiating iPSCs towards a variety of neural cell types have recently unveiled promising opportunities to understand neurological diseases using patient cells.